rais incyt fair valu estim follow
approv pipelin progress
page full analyst note may
conduct analyst
govern code ethics/cod conduct
polici secur trade polici
equival invest research
interest visit
primari analyst cover compani
stock
research may
estim may
price data may
rate updat may
currenc amount express
busi strategi outlook
methodolog valu compani
busi strategi outlook
lead drug jakafi initi gain traction
drug approv sever myelofibrosi rare blood disord
jakafi stronghold mf market like continu especi
two lead competitor drug left play field
lacklust pivot trial data expand jakafi label
polycythemia vera late steroid refractori acut graft
versu host diseas may evalu drug
essenti thrombocythemia togeth push peak
sale billion
market jak inhibitor olumi baricitinib
approv europ rheumatoid arthriti
 partner seriou infect
malign weigh compet jak inhibitor
xeljanz olumi black box label thrombocytosi
cloud launch jak like rinvoq
launch back away olumi
howev think robust late-stag pipelin focus
primarili oncolog autoimmun indic
provid attract long-term growth opportun firm
second-gener jak inhibitor itacitinib recent fail
phase data first-lin treatment acut graft versu host
diseas see strong potenti topic version activ
ingredi jakafi ruxolitinib phase trial
dermatolog indic includ atop dermat vitiligo
beyond jak inhibit receiv approv pemazyr
pemigatinib second-lin cholangiocarcinoma patient
fgfr alter april studi first-lin set
well bladder cancer tumor-agnost trial remain
progress data roll begin
once-promis inhibitor program fail
also built suit asset evalu
combin immuno-oncolog indic program
preclin phase develop retifanlimab
antibodi move phase studi first-lin lung cancer
valuat summari forecast
financi summari forecast
historical/forecast data sourc morningstar estim may reflect adjust
focus discoveri develop small-molecul drug
firm lead drug jakafi treat two type rare blood cancer graft
versu host diseas partner novarti market
drug includ rheumatoid arthriti treatment olumi licens lilli
oncolog drug
cholangiocarcinoma tabrecta lung cancer pipelin includ
broad array oncolog dermatolog program
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
rais incyt fair valu estim follow
approv pipelin progress may
first-quart result
line
expect growth jakafi sale nearli
million total revenu grow
million howev april food drug administr
approv cholangiocarcinoma drug pemazyr pemigatinib
treatment relaps patient fusion
rearrang follow may fda approv
treat first-lin relaps patient specif
mutat new case metastat non-small-cel
lung cancer boost valuat addit
ad retifanlimab
antibodi partnership
valuat model firm brink
begin phase chemo combin studi first-lin
lung cancer expect phase data anal cancer later
year could lead regulatori file altogeth
chang rais fair valu estim
share look fairli valu core hematolog drug
jakafi support narrow moat progress build
oncolog portfolio beyond jakafi well enter
alreadi begun launch pemazyr
focus target group doctor mani also
experi jakafi virtual market need
ramp test mutat lead us believ launch
gradual nich howev approv could also
eventu extend bladder cancer data expect
model potenti peak sale near million
also benefit cross-sel opportun
lymphoma drug tafasitamab come recent
partnership morphosi receiv fda
approv august therapi help build
jakafi establish presenc jakafi could see
expand sale combin
parsaclisib pim
myelofibrosi
jakafi alreadi grow well acut graft-
versus-host diseas data chronic set
expect later year approv tabrecta less
impact sharehold firm receiv
royalti novarti
dermatolog jakafi plan file approv ruxolitinib
cream treatment atop dermat end
year base phase data present april despit
potenti challeng enrol vitiligo phase
program due pandem enrol still track
data expect overal remain bullish
ruxolitinib potenti indic although
placebo compar atop dermat like mean
treatment second-lin option follow
jakafi immunolog drug olumi partner lilli
studi treatment patient
although yet incorpor potenti
sale indic due uncertainti around efficaci
price treatment/prevent option
jakafi alreadi one phase studi ruxcovid patient
cytokin storm ventil
start second studi jakafi patient
mechan ventil acut respiratori distress
syndrom studi flexibl enough includ
remdesivir combin could allow addit
efficaci see result third quarter olumi
part niaid adapt trial anoth arm studi
focus remdesivir
rais fair valu estim per
share follow approv cholangiocarcinoma
drug pemazyr lung cancer drug tabrecta well
decis model probabl approv
antibodi retifanlimab enter phase lung
cancer tabrecta royalti stream expect sale
pemazyr increas high million perhap
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
valu model enter early-stag
given depend hand market
drug regulatori commerci risk pipelin
believ firm warrant high uncertainti rate
bull-cas scenario assum jakafi success
expand indic see extend patent
protect key late-stag pipelin candid
higher probabl approv greater oper
leverag result per share fair valu estim
bear-cas scenario model jakafi struggl
penetr mpn market sever gener
roughli
probabl approv pipelin drug oper
cost result signific financi burden
base case result fair valu drop per
myeloprolif neoplasm mpn market
includ mf pv merit narrow econom moat rate
firm heavili depend jakafi sale nearli
revenu recent hit profit within
past year howev lack near-term threat
jakafi domin mf pv popul
incyt strong price power give us confid
compani gener return cost capit
forese futur
strong competit posit thank
jakafi franchis myeloprolif neoplasm
treatment approv food drug
administr myelofibrosi approv
polycythemia vera refractori patient drug
higher drug also see approv bladder cancer data
expect tafasitamab continu model
peak sale roughli billion year
approv use probabl approv
jakafi continu strong perform mf pv
launch gvhd drug continu see strong volum
growth prospect competit landscap also still
strong bristol newli approv inreb narrow
label black box warn model peak sale
billion next-gener jak itacitinib
still trial chronic gvhd prophylaxi assum
probabl approv follow drug failur
acut indic
olumi market eli lilli receiv
royalti percentag sale addit
develop regulatori mileston project
olumi royalti revenu near million
toward end forecast period roughli sale
optimist compani partnership
checkpoint modul program direct gitr
howev yet attribut
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
signific price power first-mov advantag
compet pipelin treatment jakafi solid efficaci
safeti profil patient popul high unmet
need allow compani set averag annual price
world-wide jakafi key patent expir
exclud potenti extens give incyt
signific runway build franchis expand
gvhd
nich
pipelin competit thin recent year
forese signific near-term threat
incyt jakafi franchis mix pivot data push
potenti competitor
oncolog momelotinib phase second-lin option
cti biopharma drug pacritinib phase patient
sever
inhibitor imetelstat exit partnership geron
could enter phase roche/promedior
antifibrot modul still phase
acquisit impact biomedicin earli celgen
reviv anoth competitor program fedratinib bristol
receiv approv drug call inreb august
howev continu believ jakafi set high
bar first-lin treatment inreb expect
use patient toler jakafi
low level platelet fail jakafi therapi
robust pipelin mitig threat
futur jakafi sale recent approv pemazyr
tabrecta well collabor morphosi
tafasitamab approv build
oncolog portfolio beyond jakafi compani sever
early- late-stag candid focus primarili
oncolog dermatolog indic incyt topic
ruxolitinib file atop dermat data
vitiligo expect antibodi retifanlimab
phase lung cancer lead pipelin although sever
think posit moat trend base
potenti jakafi label expans progress
compani robust early-stag pipelin jakafi carv
strong defens market posit
addit label expans pv drug achiev
blockbust statu label expans acut chronic
graft-versus-host-diseas could boost futur jakafi
compani procur
candid immuno-oncolog target posit
well increasingli key therapeut area
compani also sever earlier-stag candid focus
primarili oncolog autoimmun indic
recent partner checkpoint modul
program direct gitr
opportun remain rel unproven incyt
healthi pipelin give firm margin error believ
strategi develop combin oncolog
regimen bode favor competit advantag
rheumatoid arthriti drug olumi receiv multipl
setback last fda approv mg
dose mg black box warn due concern
imbal thrombot event treatment
arm phase data upadacitinib approv
rinvoq gilead filgotinib expect
approv look efficaci olumi ra
base top-lin result jak inhibitor
xeljanz first market despit steep competit
believ ra market could support multipl oral jak
inhibitor given high patient churn therapi
potenti near-term catalyst
progress dim time believ uptak
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
jakafi first fda-approv treatment
rare blood disord known myelofibrosi
give strong price power market penetr
market upend monopoli
label expans
dermatolog provid near-term
catalyst firm
crowd market
thrombocytosi black box warn market
disadvantag
broad array pipelin oncolog
autoimmun program give firm larger margin
error
oth failur ido inhibitor melanoma
term asset pipelin
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
equival begin period
total avail debt servic
oblig commit
total oblig commit
adjust free
gener
gener revolv adjust
commit
end billion cash
market secur limit debt balanc sheet
like biotechnolog compani histor
oper loss high cost clinic trial
research loss financ larg
offer equiti debt secur collabor
research develop fund arrang
develop mileston partner despit heavi
 spend expect firm reach sustain
profit jakafi sale intern royalti
off-set high invest
histor post loss due heavi
research develop spend firm current
sound financi shape prolong loss eros
jakafi sale could put financi posit jeopardi
signific risk mani drug candid
never reach market jakafi phase trial failur
pancreat cancer significantli reduc
optimist predict exampl addit new
competitor jakafi could reach market erod
competit posit drug also small
molecul ensur gener competit
difficult stave goe patent melanoma
trial failur highli anticip ido inhibitor
epacadostat combin merck inhibitor
keytruda also highlight development risk associ
biotech compani furthermor olumi
demonstr attract profil conveni oral
formul ra market highli competit
demonstr launch pfizer xeljanz
disappoint even though first oral
product market abbvi newli approv rinvoq
could give olumi run money market
olumi approv less efficaci mg
dose amid concern thrombot event mg dose
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
hoppenot took ceo join
presid oncolog novarti believ
hoppenot experi establish pharma firm
valuabl pipelin matur firm
transit one-drug start-up matur
diversifi biopharmaceut compani given firm
lack sustain profit past focus
deploy capit research develop
result capital-alloc decis
judg manag howev believ firm
licens agreement eli lilli olumi dictat
favor term compani sharehold alik
substanti royalti mileston payment
although execut commerci
jakafi well without previou experi view
think would difficult go alon
competit rheumatoid arthriti market addit
firm collabor morphosi antibodi
manag strategi deploy cash gener
jakafi franchis acquir early-stag oncolog drug
fit well
ceo/chairman board/
repres date owner name posit common share held report holder issuer
share
fund
share
fund
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
rais incyt fair valu estim follow
approv pipelin progress may
first-quart result
line
expect growth jakafi sale nearli
million total revenu grow
million howev april food drug administr
approv cholangiocarcinoma drug pemazyr pemigatinib
treatment relaps patient fusion
rearrang follow may fda approv
treat first-lin relaps patient specif
mutat new case metastat non-small-cel
lung cancer boost valuat addit
ad retifanlimab
antibodi partnership
valuat model firm brink
begin phase chemo combin studi first-lin
lung cancer expect phase data anal cancer later
year could lead regulatori file altogeth
chang rais fair valu estim
share look fairli valu core hematolog drug
jakafi support narrow moat progress build
oncolog portfolio beyond jakafi well enter
alreadi begun launch pemazyr
focus target group doctor mani also
experi jakafi virtual market need
ramp test mutat lead us believ launch
gradual nich howev approv could also
eventu extend bladder cancer data expect
model potenti peak sale near million
also benefit cross-sel opportun
lymphoma drug tafasitamab come recent
partnership morphosi receiv fda
approv august therapi help build
jakafi establish presenc jakafi could see
expand sale combin
myelofibrosi
parsaclisib pim
jakafi alreadi grow well acut graft-
versus-host diseas data chronic set
expect later year approv tabrecta less
impact sharehold firm receiv
royalti novarti
dermatolog jakafi plan file approv ruxolitinib
cream treatment atop dermat end
year base phase data present april despit
potenti challeng enrol vitiligo phase
program due pandem enrol still track
data expect overal remain bullish
ruxolitinib potenti indic although
placebo compar atop dermat like mean
treatment second-lin option follow
jakafi immunolog drug olumi partner lilli
studi treatment patient
although yet incorpor potenti
sale indic due uncertainti around efficaci
price treatment/prevent option
jakafi alreadi one phase studi ruxcovid patient
cytokin storm ventil
start second studi jakafi patient
mechan ventil acut respiratori distress
syndrom studi flexibl enough includ
remdesivir combin could allow addit
efficaci see result third quarter olumi
part niaid adapt trial anoth arm studi
focus remdesivir
maintain fve incyt follow solid
fourth-quart result outlook feb
maintain per share fair valu estim
follow fourth-quart result includ slightli
lower oper expens assum
research
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
previous
incorpor jakafi sale grew almost
billion continu assum billion peak
sale drug lend support firm
narrow moat pipelin mix result
past sever month disappoint result next-
gener jak itacitinib posit data topic
ruxolitinib atop dermat promis acquisit
ex-u right morphosi lymphoma drug tafasitamab
januari lower fair valu estim follow
failur itacitinib acut graft versu host diseas
drug still trial chronic gvhd prophylaxi
reduc assum probabl approv
howev continu see promis
ruxolitinib atop dermat vitiligo ad data
quarter pivot vitiligo data like next year
model potenti billion peak sale topic
version best-sel drug addit think
gain right tafasitamab fair price
firm hematologist-focus salesforc jakafi also
serv well market new drug
receiv food drug administr approv
end year data later year first-lin
dlbcl posit could see signific upsid
current estim assum potenti sale
billion profit split morphosi
also like launch pemigatinib patient
rare form cholangiocarcinoma also
benefit experi oncolog think
key driver remain tie ruxolitinib howev
remain cautiou effort refresh jakafi
oral ruxolitinib franchis once-daili version
potenti combin regimen unless see evid
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
financi summari forecast
fiscal year end decemb
earn interest tax
return asset
return equiti
valuat summari forecast
equiti
pre-tax debt
weight averag capit
addit estim scenario avail download http //select morningstar com
equival
data tabl repres base-cas forecast compani report
currenc begin current year fair valu estim may differ
equiti valu per share shown due time valu money adjust case
probability-weight scenario analysi perform
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
fiscal year end decemb
good sold
depreci amort report separ
impair charg report separ
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
